



Neurocrine, Pfizer Announce Webcast and Conference Call on Worldwide Agreement to Develop, Promote Insomnia Treatment

December 19, 2002

SAN DIEGO, Dec. 19 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Pfizer Inc. (NYSE: PFE) today announced that the two companies will host a Conference Call and Webcast to report on their global agreement for the exclusive worldwide development and commercialization of indiplon, Neurocrine's Phase III compound for the treatment of insomnia. Gary Lyons, President and CEO of Neurocrine and Hank McKinnell, Ph.D., Pfizer's Chairman of the Board and CEO will discuss the collaboration for indiplon for multiple aspects of insomnia as well as their agreement for Neurocrine to detail Pfizer's antidepressant Zoloft(R) to U.S. psychiatrists.

The Conference Call and Webcast will be held today, Thursday, December 19, 2002 at 11:30 AM Eastern Standard Time (EST), 8:30 AM Pacific Standard Time (PST). Participants may access the live Conference Call by dialing 1-800-451-7724 (U.S.) or 1-785-830-1953 (International) and using the access code of NBIX or Neurocrine. The call can also be accessed via the Company's website at www.neurocrine.com or through a link provided by PRNewswire at: <http://www.firstcallevts.com/service/ajwz371031858gf12.html>.

If you are unable to attend the Webcast and would like further information on this announcement please contact Claudia Jones or Elizabeth Foster in the Investor Relations Department at Neurocrine Biosciences at (858) 658-7600.

A replay of the call will be available approximately two hours after the call concludes and can be accessed by dialing 1-800-283-8217 (US) or 1-402-220-0868 (International). The call will be archived until Thursday, January, 2, 2003.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at <http://www.neurocrine.com>.

SOURCE Neurocrine Biosciences, Inc.